Leiden University Medical Centre
Leiden, South Holland, 2333ZA, Netherlands
Location status: Recruiting
Location contact
F A Klok, MD, PhD, Prof
CONTACT
Justine JE Stenger, MD
CONTACT
NCT Number: NCT06833827
TORPEDO-NL will be an investigator-initiated, academically sponsored, multicentre, open-label, randomized controlled trial (RCT).
Patients with high-risk pulmonary embolism (PE) require immediate reperfusion therapy on top of anticoagulation. The standard reperfusion treatment in these patients is full-dose systemic thrombolysis. This carries a significant risk of major bleeding (10-25%) and intracranial haemorrhage (ICH, 3%). Catheter-directed thrombectomy (CDT) is a promising alternative to systemic thrombolysis with a more direct effect on reducing pulmonary artery clot burden and very likely a better safety profile. Randomized trials evaluating the safety and efficacy of CDT in high-risk patients are currently unavailable. The investigators hypothesize that in high-risk PE patients, CDT is superior to the current standard of systemic thrombolysis in terms of mortality and adverse events, i.e., is associated with a lower composite incidence of all-cause mortality, treatment failure, major bleeding and all-cause stroke. The investigators also hypothesize that CDT will lead to a shorter length of stay (LOS) at the intensive care unit (ICU) and in-hospital, faster recovery, and better long-term quality of life (QoL).
Objective: To determine whether CDT in high-risk PE relative to systemic thrombolysis is:
* more effective and safer in terms of a reduction of the composite endpoint on all-cause mortality and adverse events defined as treatment failure, major bleeding and all-cause stroke at day 30 (primary outcome) * leads to a better Desirability of Outcome Ranking (DOOR) at day 7 * associated with a lower level of oxygen supplementation at 48 hours * associated with shorter length of stay (LOS) at the intensive care unit (ICU) and in the hospital * associated with better functional recovery as well as better patient-reported outcomes such as QoL at one year * cost-effective after a time horizon of one year
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Leiden, South Holland, 2333ZA, Netherlands
Location status: Recruiting
F A Klok, MD, PhD, Prof
CONTACT
Justine JE Stenger, MD
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The intervention consists of immediate thrombectomy (thrombectomy with any approved device) without systemic/locally administered thrombolysis. Thrombectomy is performed via jugular or femoral venous access according to the instructions for use for the particular device. The catheter is advanced over a preplaced guidewire across the right heart into the pulmonary arteries to the location of proximal thrombus. Procedural therapeutic anticoagulation with heparin is administered. After removal of the dilator, the thrombus is extracted by controlled volume aspiration through an aspiration catheter using a syringe or dedicated aspiration system, with multiple aspirations performed as needed. Procedural objectives will be clearly stated prior to the intervention and patient's clinical and hemodynamic status and residual thrombus will guide the investigators to determine when to terminate the procedure. Treatment success is defined as clear evidence of right ventricular recompensation.
Other names: CDT, Thrombectomy, catheter-directed mechanical thrombectomy, mechanical thrombectomy, Catheter-based thrombectomy
Standard reperfusion treatment for high-risk PE patients is thrombolytic therapy, typically consisting of Alteplase, Urokinase, or Tenecteplase, with the idea of accelerated fragmentation of the thrombus by lytic medication given systemically.
Other names: systemic thrombolysis, full-dose systemic thrombolysis, thrombolysis, thrombolytic therapy
Time frame: Day 30
This outcome will be assessed using patient records or information provided by the treating physician. A detailed description of treatment failure is provided in outcome 3 of the secondary outcomes. Major bleeding is defined as Bleeding Academic Research Consortium (BARC)3b and BARC3c bleeding (=intracranial haemorrhage). Ischemic stroke is defined as any stroke (National Institutes of Health Stroke Scale ≥1).
Unit of measure: incidence (number and percentage).
Time frame: Day 7 and day 30
This will be assessed using patient records or information provided by the treating physician. Unit of measure: incidence (number and percentage).
Time frame: Day 7 and day 30
Treatment failure in the first six hours after randomization is defined as life-threatening hemodynamic or respiratory deterioration. This deterioration is the clinical scenario if, after randomization, the patient develops overt cardiorespiratory instability over at least 15 minutes necessitating CPR, escalation of respiratory support, or ECMO. After these first six hours, treatment failure will also be defined by increasing dosages of cardiorespiratory support (e.g. oxygen, catecholamines), and lack of improvement. Lack of improvement is defined by the presence of at least one of the following criteria: i) an equal or rising SCAI SHOCK stage, ii) an equal or rising Fraction of Inspired Oxygen (FiO2) level to maintain adequate oxygen saturation (i.e. ≥ 92%), or iii) an equal or decreasing P/F ratio.
Unit of measure: incidence (number and percentage).
Time frame: Day 7, day 30 and day 90
This will be assessed using patient records or information provided by the treating physician.
Unit of measure: incidence (number and percentage).
Time frame: Day 7 and day 30
Ischemic stroke is defined as any stroke (National Institutes of Health Stroke Scale ≥1).This will be assessed using patient records or information provided by the treating physician. Unit of measure: incidence (number and percentage).
Time frame: Day 7
This will be assessed using patient records or information provided by the treating physician. A detailed description of treatment failure is provided in outcome 3 of the secondary outcomes. Major bleeding is defined as Bleeding Academic Research Consortium (BARC)3b and BARC3c bleeding (=intracranial haemorrhage). Ischemic stroke is defined as any stroke (National Institutes of Health Stroke Scale ≥1). Unit of measure: incidence (number and percentage).
Time frame: Day 7
The DOOR concept evaluates treatment benefits and harms using efficacy, safety, and functional outcomes. Patients are classified into an ordinal global outcome based on overall desirability. The probability of a more favorable result with one treatment is assessed by comparing pairwise results, ranked by the number of days requiring organ support. Organ support includes respiratory (high-flow nasal cannula or (non-)invasive mechanical ventilation) or cardiovascular (vasopressors or inotropes). DOOR outcomes, ranked from most to least desirable: 1. Survival with no severe functional limitations, no treatment failure, and no adverse events; 2. Survival with severe functional limitations, no adverse events or treatment failure; 3. Survival with BARC3b bleeding; 4. Survival with BARC3c bleeding or stroke; 5. Survival with treatment failure; 6. Death. Functional limitations are defined by the PVFS scale (grade 4 = severe limitations).
Time frame: Day 7 and day 30
Major bleeding is defined as Bleeding Academic Research Consortium (BARC)3b and BARC3c bleeding (=intracranial haemorrhage). This will be assessed using patient records or information provided by the treating physician. Unit of measure: incidence (number and percentage).
Time frame: Day 7 and day 30
This will be assessed using patient records or information provided by the treating physician. Unit of measure: incidence (number and percentage).
Time frame: 48 hours
This will be assessed using patient records or information provided by the treating physician.
Unit of measure: LO2/min
Time frame: Up to 1 year
This will be assessed using patient records or information provided by the treating physician.
Unit of measure: time in days.
Time frame: Day 7 and after 3, 6, 9 and 12 months
This will be assessed using a selection of the questionnaires mentioned in the ICHOM Set of Patient-Centered Outcome Measures for Venous Thromboembolism. The exact questionnaires used can be found in Table 2 of the study protocol.
Time frame: 1 Year
This will be assessed using questionnaires, the exact questionnaires used can be found in Table 2 of the study protocol. A more detailed description of how cost-effectiveness and budget impact will be assessed is provided in section 10.2 of the study protocol.
Contact information is provided by the study sponsor or research team.
F. A. Klok, Prof. MD. PhD.
CONTACT
W. J.E. Stenger, MD
CONTACT
Leiden University Medical Center
Other
Acronym: TORPEDO-NL
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07617376
Acute Heart Failure (AHF), Arrhythmias
Wroclaw, Poland
View Trial DetailsNCT07280247
Cardiovascular Diseases, Embolism
Saint Cloud, Minnesota, United States
View Trial DetailsNCT07491094
Cardiovascular Diseases, Clinical Deterioration
Gothenburg, Region Västra Götaland, Sweden
View Trial DetailsNCT07436702
Cardiovascular Diseases, Disease
Milan, Milano, Italy
View Trial Details